Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Vascular factors in the genesis of dementia and the optimization of patient management

https://doi.org/10.14412/2074-2711-2019-2-106-114

Full Text:

Abstract

The review considers the problem of cognitive impairment (CI) and dementia in patients from older age groups, as well as the safety of antidementia agents with a focus on adverse cardiovascular drug reactions. Special attention is paid to the role of cardiovascular risk factors in the genesis of CI and all types of dementia. It is emphasized that the treatment of patients with CI is primarily aimed at monitoring vascular risk factors, preventing stroke and progression of chronic cerebrovascular disease, and, therefore, improving cognitive functions. Postoperative cognitive dysfunction in elderly patients, in particular during coronary artery bypass surgery, is highlighted. Non-drug and drug measures to prevent the progression of CI and dementia are described in detail. The significant importance of multimorbidity and polypragmasia in elderly patients with dementia is noted; data on the cardiovascular safety of anti-dementia drugs are presented.

About the Authors

O. D. Ostroumova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Olga Dmitrievna Ostroumova

Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;

Department of Clinical Pharmacology and Internal Medicine Propedeutics, Faculty of General Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

16, 1st Leonov St., Moscow 129226, 

8, Trubetskaya St., Build. 2, Moscow119991



A. I. Kochetkov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

Russian Clinical and Research Center of Gerontology

16, 1st Leonov St., Moscow 129226



References

1. Yakhno NN. Cognitive disorders in neurological practice. Nevrologicheskii zhurnal. 2006;(Suppl. 1 1):4-12. (In Russ.).

2. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2014. 224 p.

3. Yakhno NN, Zakharov VV, Lokshina AB i dr. Dementsii. Rukovodstvo dlya vrachei [Dementias. Guide for doctors]. Moscow: MEDpress-inform; 2011. 272 p.

4. Purandare N. Prevention of dementia: Role of vascular risk factors and cerebral emboli. Indian J Psychiatry. 2009 Jan;51 Suppl 1:S39-43.

5. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008;4(2):363-81.

6. Fisher TJ, Schwartz AC, Greenspan HN, Heinrich TW. Dementia: A complex disease with multiple etiologies and multiple treatments. Int J Psychiatry Med. 2016;51(2):171-81. doi: 10.1177/0091217416636579. Epub 2016 Mar 3.

7. Ostroumova TM, Parfenov VA, Ostroumova OD. Hypertension and cognitive impairment: the standpoint of evidence-based medicine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(4):70-6. (In Russ.). Doi: 10.14412/2074-2711-2017-4-70-76

8. Parfenov VA, Starchina YuA. Cognitive disorders in patients with essential hypertension and their treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1): 27-33. (In Russ.). doi: 10.14412/2074-27112011-130

9. Cerhan JR, Folsom AR, Mortimer JA, et al. Correlates of cognitive function in middle-aged adults: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology. 1998;44(2):95-105. doi: 10.1159/000021991

10. Obisesan TO, Obisesan OA, Martins S, et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc. 2008 Mar;56(3):501-9. doi: 10.1111/j.15325415.2007.01592.x. Epub 2008 Jan 4.

11. Parfenov VA, Starchina YuA. Cognitive disorders and their treatment in patients with essential hypertension. Nervnye bolezni. 2015;(1):16-22. (In Russ.).

12. Gorelick PB. Blood Pressure and the Prevention of Cognitive Impairment. JAMA Neurol. 2014 Oct;71(10):1211-3. doi: 10.1001/jamaneurol.2014.2014.

13. Ostroumova OD, Chernyaeva MS, Golovina OV. Atrial fibrillation as Risk Factor for Development of Cognitive Function Impairment and Dementia. Potential of Anticoagulant Therapy in Their Prevention. Kardiologiya. 2018;58(9):76–88. (In Russ.).

14. Kwok CS, Loke YK, Hale R, et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011 Mar 8;76(10):914-22. doi: 10.1212/WNL.0b013e31820f2e38.

15. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2013 Mar 5;158(5 Pt 1):338-46. doi: 10.7326/0003-4819-158-5-20130305000007.

16. Santangeli P, Di Biase L, Bai R, et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm. 2012 Nov;9(11): 1761-8. doi: 10.1016/j.hrthm.2012.07.026. Epub 2012 Aug 2.

17. Goette A, Kalman JM, Aguinaga L, et al. EHRA / HRS / APHRS /SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016 Oct;18(10):1455-1490. Epub 2016 Jul 8.

18. Ostroumova OD, Shikh EV, Rebrova EV, Ryazanova AYu. Statin Therapy and Cognitive Impairment: Benefit or Harm? Ratsional'naya Farmakoterapiya v Kardiologii 2018;14(4): 529-36. (In Russ.).

19. Freeman LR, Granholm AC. Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet. J Cereb Blood Flow Metab. 2012 Apr;32(4):643-53. doi: 10.1038/jcbfm.2011.168. Epub 2011 Nov 23.

20. Davidson TL, Monnot A, Neal AU, et al. The effects of a high-energy diet on hippocampaldependent discrimination performance and blood-brain barrier integrity differ for dietinduced obese and diet-resistant rats. Physiol Behav. 2012 Aug 20;107(1):26-33. doi: 10.1016/j.physbeh.2012.05.015. Epub 2012 May 23.

21. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14-20. doi: 10.1159/000026149

22. Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 1995 Jun;45(6):1092-6.

23. Ostroumova OD, Surkova EV, Shikh EV, et al. Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs. Sakharnyi diabet. 2018;21(4):307-18 (In Russ.).

24. Umegaki H. Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging. 2014 Jun 28;9:1011-9. doi: 10.2147/CIA.S48926. eCollection 2014.

25. Sadanand S, Balachandar R, Bharath S. Memory and executive functions in persons with type 2 diabetes: a meta-analysis. Diabetes Metab Res Rev. 2016 Feb;32(2):132-42. doi: 10.1002/dmrr.2664. Epub 2015 Jun 22.

26. Vincent C, Hall PA. Executive Function in Adults With Type 2 Diabetes: A Meta-Analytic Review. Psychosom Med. 2015 Jul-Aug;77(6): 631-42. doi: 10.1097/PSY.0000000000000103.

27. Mansur RB, Lee Y, Zhou AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018 Feb;30(1):38-50.

28. Starchina YuA, Parfenov VA. Cognitive disorders in cerebrovascular diseases: diagnosis and treatment. Russkii meditsinskii zhurnal. 2008;16(12):1650-2. (In Russ.).

29. Madhavan MV, Gersh BJ, Alexander KP, et al. Coronary Artery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018 May 8; 71(18):2015-2040. doi: 10.1016/j.jacc.2017.12.068.

30. Alekseevich GYu, Rodikov MV, Mozheiko EYu, et al. Problems of cognitive dysfunction after coronary artery bypass grafting. Sibirskoe meditsinskoe obozrenie. 2015;(6):30-6. (In Russ.).

31. Petrova MM, Prokopenko SV, Eremina OV, Kaskaeva DS. Cognitive impairments in patients undergoing coronary bypass surgery under artificial circulation. Sibirskoe meditsinskoe obozrenie. 2015;(3):25-32. (In Russ.).

32. Bhamidipati D, Goldhammer JE, Sperling MR, et al. Cognitive Outcomes After Coronary Artery Bypass Grafting. J Cardiothorac Vasc Anesth. 2017 Apr;31(2):707-718. doi: 10.1053/j.jvca.2016.09.028. Epub 2016 Sep 28.

33. Mahanna EP, Blumenthal JA, White WD, et al. Defining neuropsychological dysfunction after coronary artery bypass grafting. Send to Ann Thorac Surg. 1996 May;61(5):1342-7.

34. Newman MF, Kirchner JL, Phillips-Bute B, et al; Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001 Feb 8;344(6):395-402. doi: 10.1056/NEJM200102083440601

35. Vedin J, Nyman H, Ericsson A, et al. Cognitive function after on or off pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2006 Aug;30(2):305-10. Epub 2006 Jul 7.

36. Lund C, Sundet K, Tenn∅e B, et al. Cerebral ischemic injury and cognitive impairment after off-pump and on-pump coronary artery bypass grafting surgery. Ann Thorac Surg. 2005 Dec;80(6):2126-31. doi: 10.1016/j.athoracsur.2005.06.012

37. Kozora E, Kongs S, Collins JF, et al. Cognitive outcomes after onversus off-pump coronary artery bypass surgery. Ann Thorac Surg. 2010 Oct;90(4):1134-41. doi: 10.1016/j.athoracsur.2010.05.076.

38. Joudi M, Fathi M, Harati H, et al. Evaluating the incidence of cognitive disorder following off-pump coronary artery bypasses surgery and its predisposing factors. Anesth Pain Med. 2014 Sep 15;4(4):e18545. doi: 10.5812/aapm.18545. eCollection 2014 Oct.

39. Yang J, Fan C, Pan L, et al. C-reactive protein plays a marginal role in cognitive decline: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015 Feb;30(2):156-65. doi: 10.1002/gps.4236. Epub 2014 Dec 5.

40. Doganci S, Gunaydin S, Kocak OM, et al. Impact of the intensity of microemboli on neurocognitive outcome following cardiopulmonary bypass. Perfusion. 2013 May;28(3):256-62. doi: 10.1177/0267659112470693. Epub 2013 Feb 4.

41. Barbut D, Lo YW, Gold JP, et al. Impact of embolization during coronary artery bypass grafting on outcome and length of stay. Ann Thorac Surg. 1997 Apr;63(4):998-1002. doi: 10.1016/S0003-4975(96)01254-4

42. Rodriguez RA, Rubens FD, Wozny D, Nathan HJ. Cerebral emboli detected by transcranial Doppler during cardiopulmonary bypass are not correlated with postoperative cognitive deficits. Stroke. 2010 Oct;41(10): 2229-35. doi: 10.1161/STROKEAHA.110.590513. Epub 2010 Aug 19.

43. Van Dijk D, Kalkman CJ. Why are cerebral microemboli not associated with cognitive decline? Anesth Analg. 2009 Oct;109(4):1006-8. doi: 10.1213/ANE.0b013e3181b5af06.

44. Nathan HJ, Wells GA, Munson JL, Wozny D. Neuroprotective effect of mild hypothermia in patients undergoing coronary artery surgery with cardiopulmonary bypass: a randomized trial. Circulation. 2001 Sep 18; 104(12 Suppl 1):I85-91.

45. Ghaffary S, Ghaeli P, Talasaz AH, et al. Effect of memantine on post-operative cognitive dysfunction after cardiac surgeries: a randomized clinical trial. Daru. 2017 Nov 21;25(1): 24. doi: 10.1186/s40199-017-0190-0.

46. Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.

47. Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep. 2010 Feb;12(1):20-7. doi: 10.1007/s11920-009-0085-y.

48. Parfenov VA, Starchina YuA, Yakhno NN. Eprosartan (Teveten) in the prevention of re-stroke and cognitive impairment. Nevrologicheskii zhurnal. 2007;(1):46-51. (In Russ.).

49. World Health Organization. Dementia: a public health priority. World Health Organization; 2013. 102 p. http://www.who.int/iris/handle/10665/112502

50. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci. 2005 Mar 15;229-230:43-9. Epub 2004 Dec 23.

51. Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. Int J Geriatr Psychiatry. 2001 Aug;16(8):751-61.

52. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3:CD003154. doi: 10.1002/14651858.CD003154.pub6.

53. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006 Aug; 14(8):704-15.

54. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008 Feb;13(1):97-107.

55. Schmidt R, Ropele S, Pendl B, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1312-7. doi: 10.1136/jnnp.2007. 141648. Epub 2008 Jun 27.

56. Cychev DA. Polipragmaziya v klinicheskoi praktike: problema i resheniya [Polypragmasy in clinical practice: problem and solution]. 2nd edition. Saint-Petersburg: Professiya; 2018. 272 p.

57. Prince M, Wimo AG, Ali GC, et al. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International; 2015. 87 p.

58. Van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7. doi: 10.1136/jnnp.2005.082867

59. Tonelli M, Wiebe N, Straus S, et al; Alberta Kidney Disease Network. Multimorbidity, dementia and health care in older people: a population-based cohort study. CMAJ Open. 2017 Aug 14;5(3):E623-E631. doi: 10.9778/cmajo.20170052.

60. Howes LG. Cardiovascular effects of drugs used to treat Alzheimer's disease. Drug Saf. 2014 Jun;37(6):391-5. doi: 10.1007/s40264014-0161-z.

61. Gallini A, Sommet A, Montastruc JL; French PharmacoVigilance Network. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf. 2008 Sep;17(9): 877-81. doi: 10.1002/pds.1620.

62. San-Juan-Rodriguez A, Zhang Y, He M, Hernandez I. Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease. JAMA Netw Open. 2019 Mar 1;2(3):e190213. doi: 10.1001/jamanetworkopen.2019.0213.


For citation:


Ostroumova O.D., Kochetkov A.I. Vascular factors in the genesis of dementia and the optimization of patient management. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):106-114. (In Russ.) https://doi.org/10.14412/2074-2711-2019-2-106-114

Views: 62


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)